

Juan Valle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3352782/juan-valle-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

286
papers

18,849
citations

55
h-index

134
g-index

316
ext. papers

24,381
ext. citations

6.7
avg, IF

6.65
L-index

#	Paper	IF	Citations
286	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).. <i>ESMO Open</i> , 2022 , 7, 100377	6	2
285	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 378-378	2.2	20
284	Perspective on Immunotherapy Use in Biliary Tract Cancer 2022 , 1		
283	Hepatopancreaticobiliary Cancer in Older Adults with Frailty 2022 , 421-445		
282	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102568	2.2	4
281	ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.. <i>ESMO Open</i> , 2022 , 7, 100392	6	
280	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers.. <i>ESMO Open</i> , 2022 , 7, 100417	6	0
279	Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review. <i>Neuroendocrinology</i> , 2021 , 111, 354-369	5.6	6
278	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. <i>Journal of Hepatology</i> , 2021 ,	13.4	10
277	Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer: Validation of an Algorithm for Dose Escalation and Management. <i>Pancreas</i> , 2021 , 50, 1254-1259	2.6	2
276	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 101, 102299	14.4	
275	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021 , 73, 2311-2325	11.2	13
274	HPB cancers in older patients inclusion of older/senior patients in clinical trials. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 597-602	3.6	2
273	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 94, 102168	14.4	1
272	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	1
271	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 301-307	5.9	3
270	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. <i>Cancer</i> , 2021 , 127, 2674-2682	6.4	2

269	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2021 , 22, 690-701	21.7	100
268	Long-term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. <i>Neuroendocrinology</i> , 2021 ,	5.6	2
267	Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol. <i>BMJ Open</i> , 2021 , 11, e042067	3	2
266	The Impact of Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. <i>Frontiers in Endocrinology</i> , 2021 , 12, 654975	5.7	1
265	Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021 , 13,	6.6	3
264	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103328	7	7
263	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021 , 39, 2304-2312	23.2	8
262	Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2021 , 22, e288-e289	21.7	1
261	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 583-590	3.6	6
260	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 569-575	3.6	2
259	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021 , 26, e669-e678	5.7	5
258	Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". <i>British Journal of Cancer</i> , 2021 , 124, 679-680	8.7	
257	Biliary tract cancer. <i>Lancet, The</i> , 2021 , 397, 428-444	40	87
256	Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 266-266	2.2	21
255	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021 , 144, 200-214	7.5	4
254	In Reply. <i>Oncologist</i> , 2021 , 26, e903-e904	5.7	
253	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 975-983	5.9	1
252	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. <i>British Journal of Cancer</i> , 2021 , 125, 911-919	8.7	0

251	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2248-2255	3.6	0
250	Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. <i>Cancer Cell</i> , 2021 , 39, 1227-1244.e20	24.3	32
249	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102258	14.4	9
248	Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2021 , 13, 1073-1085	3.4	0
247	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. <i>JAMA Oncology</i> , 2021 , 7, 1669-1677	13.4	31
246	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 1468-1482	21.7	2
245	Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity 2021 , 681-696		
244	External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study. <i>Neuroendocrinology</i> , 2021 ,	5.6	1
243	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.. <i>Nature Communications</i> , 2021 , 12, 7336	17.4	4
242	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 200-210	9.7	53
241	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. <i>Pancreatology</i> , 2020 , 20, 668-675	3.8	7
240	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine neoplasms (NEN). <i>BMC Cancer</i> , 2020 , 20, 1527	3	6
239	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020 , 21, 796-807	21.7	264
238	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. <i>Medical Oncology</i> , 2020 , 37, 61	3.7	5
237	Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020 , 32, 364-369	4.2	5
236	Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. <i>Journal of Hepatology</i> , 2020 , 73, 170-185	13.4	107
235	Pancreatic cancer. <i>Lancet, The</i> , 2020 , 395, 2008-2020	40	453
234	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355

233	The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology. <i>ESMO Open</i> , 2020 , 5, e000709	6	4
232	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020 , 123, 709-713	8.7	13
231	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 1035-1043.e2	2.4	19
230	The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020 , 49, 201-207	2.6	4
229	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. <i>British Journal of Cancer</i> , 2020 , 122, 971-977	8.7	13
228	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 398-411	21.7	85
227	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 1760-1768	8.7	4
226	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 477-477	2.2	19
225	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS600-TPS600	2.2	11
224	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020 , 27, 4756-4777	4.3	10
223	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020 , 16, 1069-1081	3.6	12
222	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020 , 73, 1109-1117	13.4	9
221	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101936	14.4	34
220	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLIFF Study. <i>BMJ Open</i> , 2020 , 10, e027630	3	2
219	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1047-1059	8.7	23
218	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with rearrangements. <i>Future Oncology</i> , 2020 , 16, 2385-2399	3.6	39
217	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020 , 12,	6.6	4
216	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020 , 137, 144-147	7.5	2

215	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102084	14.4	18
214	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020 , 20, 1682-1688	3.8	5
213	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	25
212	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020 , 12,	6.6	1
211	Temozolomide-Capcitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. <i>Neuroendocrinology</i> , 2020 , 110, 155-157	5.6	7
210	Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020 , 110, 688-696	5.6	3
209	Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015. <i>British Journal of Cancer</i> , 2019 , 121, 966-972	8.7	21
208	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. <i>JAMA Surgery</i> , 2019 , 154, 1038-1048 ^{5.4}		63
207	Outcomes in patients 30 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. <i>Medical Oncology</i> , 2019 , 36, 85	3.7	4
206	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2019 , 109, 100-112	5.6	14
205	Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). <i>Neuroendocrinology</i> , 2019 , 108, 317-327	5.6	9
204	Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. <i>Future Oncology</i> , 2019 , 15, 1219-1230	3.6	12
203	Biliary tract cancers: current knowledge, clinical candidates and future challenges. <i>Cancer Management and Research</i> , 2019 , 11, 2623-2642	3.6	47
202	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2019 , 20, 663-673	21.7	392
201	Medical treatment for cholangiocarcinoma. <i>Liver International</i> , 2019 , 39 Suppl 1, 123-142	7.9	49
200	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2019 , 119, 932-940	2.8	8
199	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1015-1027	2.2	157
198	F-fluorodeoxyglucose positron emission tomography (FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019 , 71, 115-129	13.4	35

197	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2571-2580	2.2	28
196	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019 , 9, 11610	4.9	18
195	Targeted therapy for cholangiocarcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 661-662:8.8	2	
194	Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. <i>Cancer Management and Research</i> , 2019 , 11, 7537-7556	3.6	3
193	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	5
192	ABC-06 A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine	2.2	129
191	Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4106-4106	2.2	19
190	Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4155-TPS4155	2.2	12
189	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS468-TPS468	2.2	4
188	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019 , 8, 37	2.3	6
187	Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019 , 8, 43	2.3	7
186	Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. <i>Neuroendocrinology</i> , 2019 , 108, 45-53	5.6	11
185	Novel Treatments for Advanced Cholangiocarcinoma 2019 , 227-243		
184	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. <i>Pancreatology</i> , 2019 , 19, 97-104	3.8	29
183	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). <i>Clinical and Translational Oncology</i> , 2019 , 21, 950-953	3.6	2
182	Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. <i>Neuroendocrinology</i> , 2019 , 108, 7-17	5.6	12
181	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019 , 269, 520-529	7.8	127
180	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , 2018 , 118, 947-954	8.7	23

179	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. <i>Oncology Research and Treatment</i> , 2018 , 41, 298-304	2.8	6
178	Circulating Tumor Cells 2018 , 1325-1360		1
177	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2018 , 118, 1084-1088	8.7	5
176	68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management. <i>Neuroendocrinology</i> , 2018 , 106, 128-138	5.6	8
175	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. <i>Neuroendocrinology</i> , 2018 , 106, 211-220	5.6	24
174	A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related adenocarcinoma). <i>Human Pathology</i> , 2018 , 72, 18-27	3.7	14
173	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. <i>Cancers</i> , 2018 , 10,	6.6	14
172	Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1486-1493	3.6	7
171	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 723-731	4.2	26
170	PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. <i>ESMO Open</i> , 2018 , 3, e000379	6	12
169	PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) Part of Precision-Panc.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4158-TPS4158	2.2	3
168	ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS537-TPS537	2.2	3
167	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018 , 9, 14922-14938	3.3	21
166	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018 , 118, 181-188	8.7	15
165	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , 2018 , 9, 4672	17.4	32
164	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. <i>European Journal of Cancer</i> , 2018 , 105, 1-9	7.5	41
163	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018 , 13, e0206007	3.7	10
162	Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 947-958	2.1	4

161	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018 , 70, 168-177	14.4	41
160	Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. <i>Clinical Therapeutics</i> , 2018 , 40, 952-962.e2	3.5	16
159	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. <i>British Journal of Cancer</i> , 2018 , 119, 27-35	8.7	14
158	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. <i>Cancer</i> , 2017 , 123, 888-890	6.4	2
157	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 1011-1024	40	999
156	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 486-499	21.7	47
155	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. <i>Human Pathology</i> , 2017 , 66, 239-240	3.7	
154	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. <i>Annals of Oncology</i> , 2017 , 28, 1309-1315	10.3	63
153	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. <i>Neuroendocrinology</i> , 2017 , 105, 281-294	5.6	66
152	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. <i>Neuroendocrinology</i> , 2017 , 105, 212-244	5.6	196
151	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. <i>Neuroendocrinology</i> , 2017 , 105, 266-280	5.6	82
150	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 141-157	9.6	79
149	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017 , 10, 5013-5030	4.4	5
148	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. <i>Journal of Clinical Oncology</i> , 2017 , 35, 14-23	2.2	201
147	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1411-1422	21.7	49
146	New molecular and immunotherapeutic approaches in biliary cancer. <i>ESMO Open</i> , 2017 , 2, e000152	6	20
145	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	18
144	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017 , 7, 943-962	24.4	254

143	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017 , 17, 262	4.8	12
142	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017 , 19, 50	6.3	12
141	The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1425-1436	7.4	183
140	Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. <i>Annals of Oncology</i> , 2017 , 28, 339-343	10.3	103
139	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. <i>Clinical and Translational Oncology</i> , 2017 , 19, 579-586	3.6	24
138	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
137	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4006-4006	2.2	109
136	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 342-342	2.2	1
135	Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS509-TPS509	2.2	5
134	Circulating Tumour Cells 2017 , 1-36		
133	Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 452-452	2.2	
132	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016 , 27, 134-40	10.3	69
131	Current Status on Cholangiocarcinoma and Gallbladder Cancer. <i>Liver Cancer</i> , 2016 , 6, 59-65	9.1	51
130	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. <i>British Journal of Cancer</i> , 2016 , 115, 420-4	8.7	7
129	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v28-v37	10.3	318
128	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2016 , 23, 563-70	5.7	17
127	Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. <i>Future Oncology</i> , 2016 , 12, 2561-2578	3.6	3
126	Telotristat ethyl: a new option for the management of carcinoid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2487-2498	4	22

125	Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. <i>Annals of Clinical Biochemistry</i> , 2016 , 53, 554-60	2.2	42
124	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. <i>BMC Cancer</i> , 2016 , 16, 153	4.8	49
123	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. <i>Cancer Treatment Reviews</i> , 2016 , 44, 26-41	14.4	34
122	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. <i>Digestive and Liver Disease</i> , 2016 , 48, 552-558	3.3	33
121	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2016 , 387, 968-977	40	694
120	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 158-69	7	8
119	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4090-4090	2.2	5
118	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 309-309	2.2	5
117	Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 309-309	2.2	5
116	Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 315-315	2.2	5
115	Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. <i>Cancer Research Frontiers</i> , 2016 , 2, 352-367		9
114	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6065-75	5.6	15
113	Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 382-382	2.2	
112	Prognostic influence of clinical biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) receiving sorafenib: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 304-304	2.2	2
111	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4148-TPS4148	2.2	
110	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 819-827	2.8	14
109	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. <i>World Journal of Gastroenterology</i> , 2016 , 22, 7175-85	5.6	20
108	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. <i>Targeted Oncology</i> , 2016 , 11, 815-824	5.24	33

107	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. <i>Surgical Oncology</i> , 2016 , 25, 223-8	2.5	11
106	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. <i>British Journal of Cancer</i> , 2016 , 114, 965-71	8.7	34
105	Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. <i>British Journal of Cancer</i> , 2016 , 115, 1032-1038	8.7	17
104	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1381-8	7.5	16
103	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. <i>European Journal of Cancer</i> , 2015 , 51, 1694-703	7.5	16
102	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 967-78	21.7	174
101	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2405-6	2.2	7
100	Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1099-114	3.5	11
99	The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2015 , 29, 333-43	2.5	26
98	Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1511-9	5.6	84
97	Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland. <i>Clinical Oncology</i> , 2015 , 27, 741-6	2.8	12
96	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 201-11	1.6	143
95	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 115-22.e1-2	3.8	36
94	A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4121-4121	2.2	3
93	Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 276-276	2.2	2
92	Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3545-3545	2.2	
91	Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15197-e15197	2.2	
90	Prognostic score in high-grade gastrointestinal neuroendocrine tumours (GI-NETs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4089-4089	2.2	

89	Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt347	9.7	191
88	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 175-83	7.4	72
87	A comparison of diagnostic imaging modalities for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 545-550	3.6	31
86	Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 504-12	2.2	254
85	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 829-40	21.7	237
84	Erratum to A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours [Cancer Treat Rev 40 (2014) 376-89]. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1037	14.4	2
83	Circulating biomarkers in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 323-32	3.5	46
82	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. <i>Annals of Oncology</i> , 2014 , 25, 391-8	10.3	239
81	Methods for adjusting for bias due to crossover in oncology trials. <i>Pharmacoeconomics</i> , 2014 , 32, 533-46	4.4	31
80	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology, The</i> , 2014 , 15, 601-11	21.7	298
79	BINGO: targeted therapy for advanced biliary-tract cancer. <i>Lancet Oncology, The</i> , 2014 , 15, 778-80	21.7	4
78	Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. <i>British Journal of Cancer</i> , 2014 , 111, 1703-9	8.7	27
77	Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease. <i>Neuroendocrinology</i> , 2014 , 99, 85-93	5.6	22
76	Second-line chemotherapy in advanced biliary cancer: a systematic review. <i>Annals of Oncology</i> , 2014 , 25, 2328-2338	10.3	196
75	Reply to the letter to the editor 'second-line chemotherapy in advanced biliary cancer: the present now will later be past' by Vivaldi et al. <i>Annals of Oncology</i> , 2014 , 25, 2444-2445	10.3	1
74	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1230-8	14.4	31
73	Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. <i>Endocrine-Related Cancer</i> , 2014 , 21, R485-93	5.7	18
72	Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 430-4	3	19

71	Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer</i> , 2014 , 50, 902-11	7.5	45
70	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. <i>Translational Oncology</i> , 2014 , 7, 55-64	4.9	15
69	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. <i>Cancer Treatment Reviews</i> , 2014 , 40, 376-89	14.4	40
68	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3556-3556	2.2	3
67	Analysis of progression-free survival in the new EPOC study in an all wild-type population.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3566-3566	2.2	1
66	Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 272-272	2.2	3
65	Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors. <i>The Journal of Oncopathology</i> , 2014 , 2, 15-25		2
64	Should Patients with Resected Bile Duct Cancer Receive an Adjuvant Treatment?. <i>The Journal of Oncopathology</i> , 2014 , 2, 57-68		3
63	Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15253-e15253	2.2	
62	Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4111-4111	2.2	2
61	Clinical Management of Targeted Therapies in Neuroendocrine Tumours 2014 , 141-154		
60	Efficacy and safety of cisplatin and gemcitabine (CG) chemotherapy for advanced biliary tract cancer (ABC) in jaundiced patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 294-294	2.2	
59	Outcome of second-line chemotherapy for biliary tract cancer. <i>European Journal of Cancer</i> , 2013 , 49, 1511	7.5	40
58	A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3504-3504	2.2	26
57	HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4006-4006	2.2	8
56	Pilot, proof-of-concept studies for determining the feasibility of the use of FLT-PET in patients with pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4146-TPS4146	2.2	1
55	A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA4004-LBA4004	2.2	12
54	The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. <i>PLoS ONE</i> , 2013 , 8, e73679	3.7	33

53	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. <i>British Journal of Cancer</i> , 2012 , 106, 508-16	8.7	196
52	Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 147-56	27.4	381
51	Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4118-4118	2.2	10
50	Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4121-4121	2.2	1
49	Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , 2011 , 364, 501-13	59.2	1817
48	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 31-9	7	27
47	Sunitinib for advanced pancreatic neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1817-27	3.5	5
46	A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. <i>Investigational New Drugs</i> , 2011 , 29, 1029-37	4.3	229
45	Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1111-7	3.5	12
44	Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2004-10	2.2	132
43	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. <i>Annals of Oncology</i> , 2011 , 22, 2042-2048	10.3	167
42	Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. <i>British Journal of Cancer</i> , 2010 , 103, 315-23	8.7	8
41	Reply: Guesstimates are not good enough for determining what is happening in routine care. <i>British Journal of Cancer</i> , 2010 , 103, 1887-1888	8.7	78
40	Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1073-81	27.4	958
39	Advances in the treatment of metastatic or unresectable biliary tract cancer. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii345-8	10.3	55
38	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. <i>European Journal of Cancer</i> , 2010 , 46, 526-33	7.5	25
37	Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. <i>New England Journal of Medicine</i> , 2010 , 362, 1273-81	59.2	2429
36	Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. <i>Clinical Oncology</i> , 2010 , 22, 570-7	2.8	12

35	Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4003-4003	2.2	4
34	Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2010 , 28, e13580-e13580	2.2	2
33	ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2010 , 28, TPS218-TPS218	2.2	2
32	Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5513-8	2.2	606
31	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. <i>British Journal of Cancer</i> , 2009 , 101, 621-7	8.7	200
30	UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. <i>Pharmacogenomics</i> , 2009 , 10, 733-9	2.6	31
29	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2008 , 99, 577-83	8.7	7
28	A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 2726-31 ^{12.9}	12.9	37
27	Pneumoperitoneum following percutaneous biliary intervention: not necessarily a cause for alarm. <i>CardioVascular and Interventional Radiology</i> , 2008 , 31, 439-43	2.7	3
26	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 579-85	3.5	12
25	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. <i>Supportive Care in Cancer</i> , 2008 , 16, 201-8	3.9	79
24	A phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4636-4636	2.2	4
23	Metastatic colorectal cancer: current systemic treatment options. <i>Drugs</i> , 2007 , 67, 1851-67	12.1	30
22	Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. <i>British Journal of Cancer</i> , 2007 , 96, 38-43	8.7	10
21	Phase I evaluation of a fully human anti- α v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 2128-35	12.9	124
20	Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. <i>Clinical Cancer Research</i> , 2007 , 13, 7113-8	12.9	65
19	Patients with pancreatic cancer participating in clinical trials: are targets being met, and if not, why?. <i>Pancreas</i> , 2007 , 34, 269-70	2.6	1
18	Cytotoxic chemotherapy for advanced, non-resectable colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2007 , 33, S17-S23	3.6	

17	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (LV) (SCOUT) in patients with advanced colorectal cancer (ACRC): A phase I/II study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4084-4084	2.3	4
16	Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. <i>Clinical Cancer Research</i> , 2006 , 12, 3416-24	12.9	134
15	A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing?. <i>Pancreas</i> , 2006 , 32, 51-7	2.6	7
14	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. <i>British Journal of Cancer</i> , 2006 , 95, 450-6	8.7	9
13	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006 , 132, 41-4	4.9	7
12	Irinotecan with bolus and infusional 5-fluorouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-fluorouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting. <i>Clinical Oncology</i> , 2005 , 17, 666	2.8	
11	Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. <i>Journal of Clinical Oncology</i> , 2005 , 23, 973-81	2.2	158
10	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. <i>British Journal of Cancer</i> , 2005 , 92, 628-30	8.7	19
9	Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2004 , 91, 1447-52	8.7	4
8	Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2003 , 88, 1153-1154	8.7	78
7	Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1996-2004	2.2	389
6	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. <i>Cancer</i> , 2001 , 92, 601-84	6.4	44
5	Pharmacokinetics of a hematoregulatory peptide (SK&F107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy. <i>Pharmaceutical Research</i> , 2000 , 17, 385-90	4.5	2
4	<i>Citrobacter freundii</i> and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. <i>Annals of Oncology</i> , 1997 , 8, 405	10.3	5
3	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. <i>European Journal of Cancer</i> , 1997 , 33, 2183-93	7.5	50
2	Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. <i>European Journal of Cancer</i> , 1997 , 33, 2171-82	7.5	11
1	<i>Citrobacter freundii</i> and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. <i>Clinical Oncology</i> , 1997 , 9, 172-5	2.8	6